학술논문
This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes.
Document Type
Article
Author
Source
British Journal of Diabetes & Vascular Disease; Apr-Jun2016, Vol. 16 Issue 2, p88-92, 5p
Subject
Language
ISSN
14746514